The latest update is out from PureTech Health ( (GB:PRTC) ).
Seaport Therapeutics, a clinical-stage biopharmaceutical company and a Founded Entity of PureTech Health, has appointed Robert J. Hombach as the Chair of its Audit Committee. Hombach brings over 30 years of financial and operational expertise in the biotech sector, having held significant roles at companies like Baxter and Baxalta. His appointment is expected to bolster Seaport’s financial oversight as it progresses its pipeline of neuropsychiatric medicines. This strategic move highlights Seaport’s commitment to advancing its innovative Glyph technology platform, which aims to deliver transformative treatments for neuropsychiatric conditions.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to address devastating diseases. It has established a broad pipeline of therapeutics through its research and development team and extensive network of scientists and industry leaders. The company has developed 29 therapeutics, including three approved by the U.S. FDA, and advances these programs internally and through its Founded Entities.
YTD Price Performance: -12.78%
Average Trading Volume: 550,758
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £314.6M
Learn more about PRTC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com